Comparison of HER2/<i>neu</i>Status Assessed by Quantitative Polymerase Chain Reaction and Immunohistochemistry

O’Malley, Frances P.; Parkes, Robert; Latta, Eleanor; Tjan, Suzanna; Zadro, Tanya; Mueller, Rosemary E.; Arneson, Nona; Blackstein, Martin E.; Andrulis, Irene L.

doi:10.1309/vp4w-5c55-7m09-6tx3

Cited by 59 publications

(41 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With this staining kit, the rate of HER2-overexpressing bladder carcinomas was 41% in our study, which represents a roughly equivalent rate to that reported for breast carcinomas. 46,47 There is evidence of a correlation between worse prognosis and immunohistochemic HER2 overexpression in bladder cancer. Lipponen 31 reported that HER2 expression predicted recurrence-free survival in superficial tumors with a borderline significance.…”

Section: Resultsmentioning

confidence: 99%

HER2 overexpression in muscle‐invasive urothelial carcinoma of the bladder: Prognostic implications

Krüger

Weitsch

Büttner

et al. 2002

Intl Journal of Cancer

162

108

View full text Add to dashboard Cite

The HER2 (c-erbB-2) receptor is overexpressed in a variety of human malignant tumors and, in breast carcinoma, has been identified as a target for anti-HER2-directed therapy with the monoclonal antibody (MAb) trastuzumab. The aim of this retrospective study was to evaluate immunohistochemic HER2 expression in a large cohort of muscle-invasive urothelial cell carcinomas of the urinary bladder and to compare the results to pathologic characteristics and survival. Paraffin-embedded tumor specimens from 138 patients undergoing radical cystectomy for muscle-invasive bladder carcinoma were studied immunohistochemically with the Food and Drug Administration (FDA)-approved HercepTest (Dako, Glostrup, Denmark). HER2 overexpression was observed in 57 of 138 tumors (41%) and occurred more frequently in high-grade carcinomas than in low-grade carcinomas (p ‫؍‬ 0.036). No significant relationship with HER2 overexpression was registered for tumor staging and lymph node status. Kaplan-Meier curves showed a significantly worse disease-related survival (p ‫؍‬ 0.034) in patients with HER2-overexpressing tumors compared to those without HER2 overexpression. In addition to lymph node status (p ‫؍‬ 0.0001; relative risk [RR] ‫؍‬ 2.93), HER2 status (p ‫؍‬ 0.020; RR ‫؍‬ 2.22) was identified as an independent predictor for disease-related survival in a multivariate analysis. These results suggest that HER2 expression might provide additional prognostic information in patients with muscle-invasive bladder carcinomas. Because many of these patients harbor HER2-overexpressing tumors, clinical trials evaluating the efficacy of trastuzumab in bladder carcinoma are warranted.

show abstract

Section: Resultsmentioning

confidence: 99%

HER2 overexpression in muscle‐invasive urothelial carcinoma of the bladder: Prognostic implications

Krüger

Weitsch

Büttner

et al. 2002

Intl Journal of Cancer

162

108

View full text Add to dashboard Cite

show abstract

“…Similar results were obtained in our own institution. 51 The amplification of this gene has been found in 0% of special type cancers and o1% of invasive lobular carcinomas. 52 In the latter study, only one of 67 invasive lobular carcinomas was positive for HER2/neu gene amplification.…”

Section: Discussionmentioning

confidence: 99%

Invasive lobular carcinoma: to grade or not to grade

et al. 2005

Self Cite

View full text Add to dashboard Cite

Grading of invasive ductal carcinoma of no special type using the Nottingham combined histologic grading system provides independent prognostic information. The prognostic utility of grading invasive lobular carcinomas, however, has not been fully elucidated. In addition, the relationship between grade in invasive lobular carcinomas and expression of predictive biomarkers is less certain. The purpose of this study was to correlate histologic grade in invasive lobular carcinoma with known prognostic and predictive markers. All primary resections for invasive mammary carcinomas diagnosed in Mount Sinai Hospital, Toronto, between the years 1996 and 2002 were reviewed (n ¼ 1053). Of these cases, 50 were pure invasive lobular carcinoma (incidence 4.7%). The median age at diagnosis was 64 years. These tumors were graded using the Nottingham combined histologic grading system and analyzed for estrogen receptor, progesterone receptor, HER2/neu and E-cadherin expression. Tumor grade was correlated with tumor size (P ¼ 0.03), and the American Joint Committee on Cancer nodal status (P ¼ 0.05). Assessment of the individual components of grade showed that the mitotic score was highly correlated with tumor size (P ¼ 0.02), lymph node positivity (P ¼ 0.02) and overall American Joint Committee on Cancer stage (P ¼ 0.01). Estrogen receptor and progesterone receptor were highly expressed irrespective of the grade of tumor. HER2/neu protein overexpression and E-cadherin protein expression was absent in all invasive lobular carcinomas studied. We conclude that pure invasive lobular carcinoma is uncommon and occurs predominantly in postmenopausal women. Increasing tumor grade is correlated with median tumor size and the American Joint Committee on Cancer nodal stage, but not correlated with the expression of estrogen receptor, progesterone receptor, E-cadherin or HER2/neu protein overexpression.

show abstract

“…As two cores from each tumor were assessed, the larger of the two values was chosen for use in statistical analysis to minimize the effect of false negatives on the array. For ER, PgR, HER2, and p53, cutpoints to define positivity were based on previous validation studies (34,(36)(37)(38)(39). For CK5 and EGFR, the cutpoint for positivity was arbitrarily specified as !4.…”

Section: Patient Cohort and Clinical Follow-upmentioning

confidence: 99%

Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer

Mulligan

Pinnaduwage

Tchatchou

et al. 2016

Cancer Immunology Research

View full text Add to dashboard Cite

We previously observed T-bet þ lymphocytes to be associated with a good prognosis in a cohort of women with familial breast cancer. To validate this finding, we evaluated lymphocyte T-bet expression in an independent unselected prospectively accrued series of women with lymph node-negative breast carcinoma. T-bet and clinicopathologic data were available for 614 women. Hormone receptors, HER2, Ki-67, CK5, EGFR, p53, and T-bet status were determined using IHC and/or biochemical methods.

show abstract

Comparison of HER2/neuStatus Assessed by Quantitative Polymerase Chain Reaction and Immunohistochemistry

Cited by 59 publications

References 28 publications

HER2 overexpression in muscle‐invasive urothelial carcinoma of the bladder: Prognostic implications

HER2 overexpression in muscle‐invasive urothelial carcinoma of the bladder: Prognostic implications

Invasive lobular carcinoma: to grade or not to grade

Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer

Contact Info

Product

Resources

About